Amarin Corp Plc (AMRN)

[ziploc_1]

Ramfan...MND-2119 is never mentioned by Amarin even though they paid $2 million for the rights to sell Mochida products anywhere but in Japan....MND-2119 has been approved in Japan and is currently being marketed there...It is also an EPA drug, but one, which better absorbed by the body than Vascepa.

negative features

1. It would have to go through an approval process by the U.S. FDA
2. It would replace Vascepa, which Amarin has already inventoried a ton of
3. It would need a whole new marketing campaign, which Amarin can't afford
4. It would probably cost Amarin in royalties(?how much...Amarin won't divulge)

positive features

1. It would be a patented drug in the U.S. without any generic competition
2. It could be given in 2 gram capsules to produce the same blood levels as 4
gram capsules of Vascepa
3. It would be a better combination drug for a FDC drug than Vascepa